Cargando…

Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate)

Efavirenz (EFV) is a non-nucleoside reverse transcriptase inhibitor used in first-line combination antiretroviral therapy (cART). It is usually administered with nucleoside reverse transcriptase inhibitors (NRTI), many of which are substrates of OCT uptake solute carriers (SLC22A) and MATE (SLC47A),...

Descripción completa

Detalles Bibliográficos
Autores principales: Ceckova, Martina, Reznicek, Josef, Deutsch, Birgit, Fromm, Martin F., Staud, Frantisek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095608/
https://www.ncbi.nlm.nih.gov/pubmed/30114293
http://dx.doi.org/10.1371/journal.pone.0202706
_version_ 1783347970671902720
author Ceckova, Martina
Reznicek, Josef
Deutsch, Birgit
Fromm, Martin F.
Staud, Frantisek
author_facet Ceckova, Martina
Reznicek, Josef
Deutsch, Birgit
Fromm, Martin F.
Staud, Frantisek
author_sort Ceckova, Martina
collection PubMed
description Efavirenz (EFV) is a non-nucleoside reverse transcriptase inhibitor used in first-line combination antiretroviral therapy (cART). It is usually administered with nucleoside reverse transcriptase inhibitors (NRTI), many of which are substrates of OCT uptake solute carriers (SLC22A) and MATE (SLC47A), P-gp (MDR1, ABCB1), BCRP (ABCG2), or MRP2 (ABCC2) efflux transporters. The aim of this study was to evaluate the inhibitory potential of efavirenz towards these transporters and investigate its effects on the pharmacokinetics and tissue distribution of a known Oct/Mate substrate, lamivudine, in rats. Accumulation and transport assays showed that efavirenz inhibits the uptake of metformin by OCT1-, OCT2- and MATE1-expressing MDCK cells and reduces transcellular transport of lamivudine across OCT1/OCT2- and MATE1-expressing MDCK monolayers. Only negligible inhibition of MATE2-K was observed in HEK-MATE2-K cells. Efavirenz also reduced the efflux of calcein from MDCK-MRP2 cells, but had a rather weak inhibitory effect on Hoechst 33342 accumulation in MDCK-MDR1 and MDCK-BCRP cells. An in vivo pharmacokinetic interaction study in male Wistar rats revealed that intravenous injection of efavirenz or the control Oct/Mate inhibitor cimetidine significantly reduced the recovery of lamivudine in urine and greatly increased lamivudine retention in the renal tissue. Co-administration with efavirenz or cimetidine also increased the AUC(0-∞) value and reduced total body clearance of lamivudine. These data suggest that efavirenz is a potent inhibitor of OCT/Oct and MATE/Mate transporters. Consequently, it can engage in drug-drug interactions that reduce renal excretion of co-administered substrates and enhance their retention in the kidneys, potentially compromising therapeutic safety.
format Online
Article
Text
id pubmed-6095608
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-60956082018-08-30 Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate) Ceckova, Martina Reznicek, Josef Deutsch, Birgit Fromm, Martin F. Staud, Frantisek PLoS One Research Article Efavirenz (EFV) is a non-nucleoside reverse transcriptase inhibitor used in first-line combination antiretroviral therapy (cART). It is usually administered with nucleoside reverse transcriptase inhibitors (NRTI), many of which are substrates of OCT uptake solute carriers (SLC22A) and MATE (SLC47A), P-gp (MDR1, ABCB1), BCRP (ABCG2), or MRP2 (ABCC2) efflux transporters. The aim of this study was to evaluate the inhibitory potential of efavirenz towards these transporters and investigate its effects on the pharmacokinetics and tissue distribution of a known Oct/Mate substrate, lamivudine, in rats. Accumulation and transport assays showed that efavirenz inhibits the uptake of metformin by OCT1-, OCT2- and MATE1-expressing MDCK cells and reduces transcellular transport of lamivudine across OCT1/OCT2- and MATE1-expressing MDCK monolayers. Only negligible inhibition of MATE2-K was observed in HEK-MATE2-K cells. Efavirenz also reduced the efflux of calcein from MDCK-MRP2 cells, but had a rather weak inhibitory effect on Hoechst 33342 accumulation in MDCK-MDR1 and MDCK-BCRP cells. An in vivo pharmacokinetic interaction study in male Wistar rats revealed that intravenous injection of efavirenz or the control Oct/Mate inhibitor cimetidine significantly reduced the recovery of lamivudine in urine and greatly increased lamivudine retention in the renal tissue. Co-administration with efavirenz or cimetidine also increased the AUC(0-∞) value and reduced total body clearance of lamivudine. These data suggest that efavirenz is a potent inhibitor of OCT/Oct and MATE/Mate transporters. Consequently, it can engage in drug-drug interactions that reduce renal excretion of co-administered substrates and enhance their retention in the kidneys, potentially compromising therapeutic safety. Public Library of Science 2018-08-16 /pmc/articles/PMC6095608/ /pubmed/30114293 http://dx.doi.org/10.1371/journal.pone.0202706 Text en © 2018 Ceckova et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Ceckova, Martina
Reznicek, Josef
Deutsch, Birgit
Fromm, Martin F.
Staud, Frantisek
Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate)
title Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate)
title_full Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate)
title_fullStr Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate)
title_full_unstemmed Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate)
title_short Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate)
title_sort efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (oct, oct) and multidrug and toxin extrusion proteins (mate, mate)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095608/
https://www.ncbi.nlm.nih.gov/pubmed/30114293
http://dx.doi.org/10.1371/journal.pone.0202706
work_keys_str_mv AT ceckovamartina efavirenzreducesrenalexcretionoflamivudineinratsbyinhibitingorganiccationtransportersoctoctandmultidrugandtoxinextrusionproteinsmatemate
AT reznicekjosef efavirenzreducesrenalexcretionoflamivudineinratsbyinhibitingorganiccationtransportersoctoctandmultidrugandtoxinextrusionproteinsmatemate
AT deutschbirgit efavirenzreducesrenalexcretionoflamivudineinratsbyinhibitingorganiccationtransportersoctoctandmultidrugandtoxinextrusionproteinsmatemate
AT frommmartinf efavirenzreducesrenalexcretionoflamivudineinratsbyinhibitingorganiccationtransportersoctoctandmultidrugandtoxinextrusionproteinsmatemate
AT staudfrantisek efavirenzreducesrenalexcretionoflamivudineinratsbyinhibitingorganiccationtransportersoctoctandmultidrugandtoxinextrusionproteinsmatemate